Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with prostate cancer and indicated for androgen deprivation therapy (ADT)~* Decision made to prescribe ADT prior to enrolment~* Willing and able to provide written informed consent~Exclusion Criteria:~* Participation in an interventional clinical study in which any treatment or follow-up is mandated~* Treatment with a GnRH receptor antagonist other than FIRMAGON~* Had previous or is currently under hormonal management of prostate cancer, except for subjects who have undergone therapy with curative intention where neoadjuvant/adjuvant therapy allowed for maximum 6 months. Treatment should be terminated at least 6 months prior to baseline.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FIRMAGON (Type: None): None
- GnRH Agonist (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).